Genentech gets competitive in KRAS with early dealmaking push: Data Byte

It’s been a busy year for Genentech’s business development team as the company adds discovery and early clinical development deals. The latest deal — a partnership with Relay on a SHP2 inhibitor — should strengthen Genentech’s position in the competitive KRAS inhibitor landscape. 

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered with Relay Therapeutics Inc. (NASDAQ:RLAY) in a license and collaboration agreement that gives Genentech development rights to SHP-2 inhibitor RLY-1971 in exchange for $75 million up front and $25 million in near-term milestones. ...